UBS maintains Dentsply Sirona at Buy, lowers price target to $13 from $17
UBS kept Dentsply Sirona at Buy but reduced its price target to $13 from $17, a 23.5% cut. This implies a 41.9% upside from the Nov 13 close of $9.16. Recent analyst targets range from $10 to $13.
How this was made

The 30-second read
Why it matters
A lower price target can influence short-term positioning and expectations, but the lack of new operational or financial disclosures in the text limits the actionable impact.
Market read
Traders may adjust valuation expectations for XRAY based on UBS’s revised target, but the note is not a fundamental catalyst by itself.
What to watch
Price-target changes can lag or reflect model updates rather than new information; without thesis details, traders may discount the move’s durability.
Background
The article summarizes UBS’s latest analyst note on Dentsply Sirona, including a maintained Buy rating and a reduced price target.
Ticker impact
UBS maintained Dentsply Sirona at Buy and cut its price target to $13 from $17, implying a large change in valuation expectations.
Likely mild-to-moderate downside bias as the market reprices the analyst’s valuation framework, partially offset by the unchanged Buy rating.
This is a sell-side price-target revision without new company fundamentals in the text; directionally, a lower target tends to weigh on sentiment, but the maintained Buy reduces the magnitude.
Market effects
Limited spillover to dental/medical-diagnostics peers because the article is a single-bank target change, not sector guidance or regulatory action.
No clear regional macro linkage beyond general US equity sentiment.
Minimal global relevance; this is a US-listed single-name analyst update.
Counterpoint
The unchanged Buy rating may signal the analyst still sees upside, so the market may focus more on the rating than the lower target.
Key entities
- companyDentsply Sirona
UBS maintained a Buy rating and lowered its price target to $13 from $17.
- analyst_firmUBS
Issued the maintained rating and revised price target referenced in the article.





